Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

NCT06053099 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT06053099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06053099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Not applicable
Overall status
Recruiting
Start date
January 22, 2024
Completion date
October 31, 2031
Enrollment
300 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, egfr del19, egfr l858r, non small cell lung cancer